...
首页> 外文期刊>Kidney international. >Interleukin-4 ameliorates experimental glomerulonephritis and up-regulates glomerular gene expression of IL-1 decoy receptor
【24h】

Interleukin-4 ameliorates experimental glomerulonephritis and up-regulates glomerular gene expression of IL-1 decoy receptor

机译:白细胞介素4改善实验性肾小球肾炎并上调IL-1诱饵受体的肾小球基因表达

获取原文

摘要

Interleukin-4 ameliorates experimental glomerulonephritis and up-regulates glomerular gene expression of IL-1 decoy receptor. Monocytes/ macrophages and pro-inflammatory cytokines such as interleukin (IL)-1 are important in the pathogenesis of acute glomerulonephritis. The aim of this study was to examine whether IL-4, a cytokine with anti-inflammatory activity, could modulate glomerular inflammation and reduce injury in vivo. Treatment with recombinant rat IL-4 in a model of anti-glomerular basement membrane (GBM) antibody mediated glomerulonephritis in rats reduced glomerular injury. Albuminuria was less (73% less at day 4) and a lower proportion of glomeruli had capillary thrombi (79% less at day 4). In IL-4 treated rats, there was a moderate reduction in the number of macrophages in the glomeruli and also suppression of pro-inflammatory activities of the macrophages. Northern blot analysis of glomerular RNA showed that treatment with IL-4 up-regulated mRNA levels of type II IL-1 receptor (IL-1RTII). IL-1RTII, also known as IL-1 decoy receptor, may act as a decoy molecule to inhibit the effect of IL-1. To our knowledge, this is the first demonstration of (i) recombinant IL-4 reducing glomerular inflammation in vivo and (ii) a treatment that increases IL-1RTII expression in association with reduction of tissue injury in vivo.
机译:白介素4改善实验性肾小球肾炎,并上调IL-1诱饵受体的肾小球基因表达。单核细胞/巨噬细胞和促炎细胞因子如白介素(IL)-1在急性肾小球肾炎的发病机理中很重要。这项研究的目的是检查具有抗炎活性的细胞因子IL-4是否可以调节肾小球炎症并减轻体内损伤。在大鼠抗肾小球基底膜(GBM)抗体介导的肾小球肾炎模型中用重组大鼠IL-4治疗可减少肾小球损伤。蛋白尿较少(第4天减少73%),肾小球毛细血管血栓的比例较低(第4天减少79%)。在用IL-4治疗的大鼠中,肾小球中的巨噬细胞数量适度减少,并且还抑制了巨噬细胞的促炎活性。肾小球RNA的RNA印迹分析表明,用IL-4上调II型IL-1受体(IL-1RTII)的mRNA水平。 IL-1RTII,也称为IL-1诱饵受体,可以充当诱骗分子来抑制IL-1的作用。据我们所知,这是(i)重组IL-4减少体内肾小球炎症反应和(ii)与体内组织损伤减少相关的增加IL-1RTII表达的治疗的首次证明。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号